- Details
- Silke Gillessen, MD and Aurelius Omlin, MD discuss the inception of the biennial Advanced Prostate Cancer Consensus Conference (APCCC) which will be held in Basel this August. The intent of the meeting is to drive international consensus on key areas of prostate cancer practice where there are no clear guidelines or level 1 evidence. 75% of the panelists must agree on each topic to reach a consens...
|
- Details
- Oliver Sartor, MD discusses his contributions to the recent publication in JAMA Oncology on the prevalence of germline variants in prostate cancer and the implications for genetic testing guidelines. 3600 patients had various forms of germiline genetic testing performed and were available for this analysis. In the dataset, 17% of patients had germline variants and 30% of those were BRCA1/BRCA2. In...
|
- Details
- Anis Hamid and Chris Sweeney discuss their recent work studying biomarkers across the full spectrum of prostate cancer. Based on preclinical studies we understand that aggressive disease lies in the tumor genome and we see recurrent losses of certain genes in both early and advanced prostate cancer. The classic tumor suppressors that are commonly mutated across cancers, including prostate cancer,...
|
- Details
- Dan Spratt and Todd Morgan discuss the role of genomics in localized prostate cancer from the perspective of the radiation oncologist and the urologist. Based on the MUSIC registry, which represents over 90% of the urology practices across Michigan, they reveal that most of the prostate cancer patients are not receiving genomic profiling. Drs. Spratt and Morgan review each of the genomic tests inc...
|
- Details
- Alicia Morgans and Matt Cooperberg discuss the current state of contemporary active surveillance and efforts to standardize strategies nationwide. This conversation also includes discussion on informed decision making and practice patterns of active surveillance and how to tailor based on biology and genetics Biographies: Matthew Cooperberg, MD, MPH, FACS, Associate Professor, Department of Urolog...
|
- Details
- Kala Sridhar and Alicia Morgans share in a discussion on challenges and opportunities in the treatment of localized prostate cancer from the viewpoint of a medical oncologist. Conversation includes approaches for optimizing systemic therapy in localized disease and new hormonal agents, and the ICECAP initiative. Biographies: Srikala (Kala) Sridhar MD, MSc, FRCPC Medical Advisory and Research Board...
|
- Details
- Dr. May Sadik presents data from the SNMMI meeting highlighting a retrospective study in 45 patients with hormone naïve prostate cancer. The objective was to develop a completely automated method to quantify prostate gland update of 18F-choline in PET/CT images. The hope is that these preliminary data will lead to a better understanding of the relationship between this measure, the clinical data a...
|
- Details
- Ur Metser a study that was conducted to determine whether integrated 18F-fluorocholine (FCH) PET whole-body MRI (PET/WBMRI) depicts lymph node and distant metastases in patients with high-risk prostate cancer more frequently than does conventional staging. Biography: Ur Metser, MD, FRCPC, Joint Department of Medical Imaging, the University of Toronto Related Content: 18F-Fluorocholine PET Whole-Bo...
|
- Details
- Claudia Zacharias presents Gallium 6 PSMA-11 PET/MR Imaging in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer, a pilot study evaluating the detection rate for the initial diagnosis of prostate cancer and the metastatic spread for patients in the intermediate and high-risk prostate cancer risk category using 68 Ga-PSMA-11 PET/MR. She reviews the potential role of 68 Ga-PSM...
|
- Details
- (Length of Interview: 17 min) Peter Pinto highlights the paradigm shift to the use of new imaging technology for a more accurate diagnosis of prostate cancer. Targeted MRI/Ultrasound (MR/US) guided biopsy vs TRUS biopsy, full body imaging options such as PET, and Axumin® (fluciclovine F 18) as a staging tool, with mention of metabolic and focal imaging are part of this comprehensive interview. As...
|
